Obsidian TherapeuticsObsidian Therapeutics
  • About Us
    • Overview
    • Our Vision
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Our Science
    • Overview
    • Our Pipeline
    • cytoDRiVE® PLATFORM
    • Publications
    • Partners
  • Our Lead Clinical Program
    • Overview
    • OBX-115
    • Our Clinical Trial
    • Expanded Access Policy
  • Investors & Media
  • Join Our Team
    • Overview
    • Our Culture
    • Testimonials
    • Job Postings
  • Contact

Publications

ASCO (June 2026)

OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy with regulatable membrane-bound IL15 (mbIL15) in patients with immune checkpoint inhibitor (ICI)-resistant advanced melanoma

Read More

AACR (April 2026)

OBX-115 membrane-bound IL15 (mbIL15)-expressing engineered tumor-infiltrating lymphocytes (TIL) overcome target cell immune evasion related to major histocompatibility complex (MHC) silencing through both direct killing and transactivation of NK cells in patient-derived autologous non-small cell lung cancer (NSCLC) models

Read More

SITC (March 2026)

Translational data validate OBX-115 mechanism of action: Impact of dosing on clinical outcome in advanced melanoma

Read More

AACR IO (February 2026)

Translational data validate OBX-115 mechanism of action: Impact of dosing on clinical outcome in advanced melanoma

Read More

ESMO (October 2025)

Translational data validate OBX‐115 mechanism of action: Impact of dosing on clinical outcome in advanced melanoma

Read More

ASCO (June 2025)

OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy with regulatable membrane-bound IL15 (mbIL15) in patients with immune checkpoint inhibitor (ICI)-resistant advanced melanoma

Read More

ASCO (June 2025)

OBX-115 engineered tumor-infiltrating lymphocytes (TIL) with regulatable membrane-bound IL15 (mbIL15): Translational data from a single-center phase 1 trial in patients with immune checkpoint inhibitor (ICI)-resistant advanced melanoma

Read More

AACR (April 2025)

OBX-115 TIL from non-small cell lung cancer (NSCLC) are enriched for putative tumor-reactive, stem-like T cells with enhanced tumor cytotoxicity: Results from multimodal phenotypic analysis

Read More

1 2 3 … 6 Next
Obsidian Therapeutics
  • About Us
  • Our Science
  • Our Lead Clinical Program
  • Investors & Media
  • Join Our Team
  • Contact

Privacy // Terms of Use
© 2026 Obsidian Therapeutics, Inc. All Rights Reserved.

Our programs, including OBX-115, and cytoDRIVE® Platform are investigational and have not been approved by the FDA or any other regulatory agency.

Our Pipeline Job Postings
We use cookies on our website to optimize your experience, analyze site usage, and to assist with our marketing activities. By continuing to navigate our website, you consent to the use of cookies, our privacy policy and terms of use.
Accept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT